Abstract
* After its year-long safety review, the FDA has announced that it could not identify a clear relationship between bisphosphonates, drugs taken to increase bone density in postmenopausal women, and the development of serious atrial fibrillation, despite one trial that found a statistically significantly greater incidence of it with zoledronic acid (Reclast).
* Physicians and NPs may continue to prescribe bisphosphonates.